Conditions: Glioma Medulloblastoma
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 83
Healthy volunteers: no

Brief summary:
This study will assess the rate of objective confirmed tumor response of irinotecan in combination with temozolomide in children with recurrent or refractory medulloblastoma and in children with newly diagnosed high-grade glioma.

Detailed description:

Arms:
arm 1: None

Interventions: intervention 1: Irinotecan intervention 2: Temozolomide
Intervention descriptions: intervention 1: Irinotecan 10 mg/m\^2 per day on days 1-5 and days 8-12 in repeated 3 week cycles intervention 2: Temozolomide 100-125 mg/m\^2 daily on days 1-5 in repeated 3 week cycles

Protocol document: